Bristol-Myers Squibb will unload an API plant in Ireland to a South Korean company with large aspirations in contract manufacturing.

Nanjing Legend Biotech reported 100% ORR for a CAR-T product, Chi-Med touted fruquintinib's low liver toxicity, Eisai's Lenvima could challenge Bayer…

South Korean authorities aren’t letting Novartis off the hook easily in an ongoing bribery controversy.

Dr. Reddy’s is recalling 765,058 cartons of its Zenatane acne med, which was manufactured for it by compatriot Cipla.

Takeda is starting work on a €40 million plant to manufacture multiple myeloma drug Ninlaro at its site in Ireland, where it will add 40 new jobs.

Bharat Biotech has initiated a phase 1 trial of its Chikungunya vaccine, while Themis started a phase 2 of its own candidate.

Japan’s Sawai is following other drugmakers by establishing a U.S. manufacturing beachhead by acquiring a U.S. generics operation.

At ASCO's annual meeting, it's tough to sift through all the data oncology drugmakers are piling up, so we've done it for you.

Takeda’s cancer unit debuted a new face at this year’s ASCO—and the company was quick to bill it as such.

Pharma Asia